SARS-CoV-2_Webinar-V2-990x120

Event Overview
SARS-CoV-2 is characterized by its rapid spread and significant human-to-human transmission. With no approved vaccines or treatments yet available, researchers are exploring various medical interventions, including neutralizing monoclonal antibodies (mAbs), to control the global COVID-19 pandemic. The SARS-CoV-2 spike (S) glycoprotein, which promotes entry into host cells, is the main target of neutralizing antibodies. In this multisponsored webinar by The Scientist, a panel of researchers will discuss potential neutralizing antibodies currently under investigation for SARS-CoV-2 treatment.

Topics to be covered
  • Human monoclonal antibodies for SARS-CoV-2
  • SARS-CoV-2 neutralizing antibodies for global access
Tuesday, July 28, 2020
 
2:30 - 4:00 PM, Eastern Standard Time


Speakers
Crowe.png
James E. Crowe, Jr., MD
Director, Vanderbilt Vaccine Center
Professor, Pediatrics and Pathology, Microbiology and Immunology
Ann Scott Carrell Chair

Sok.png
Devin Sok, PhD
Senior Director, Antibody Discovery and Development
IAVI

biotechne.png
biotechne.png

biotechne.png

biotechne.png

biotechne.png
10x.png


BPS.png

Register Now

TS_WEBINARSIGNUP_Putting the Brakes on SARS-CoV-2: Neutralizing Antibodies July 28, 2020
You must have Javascript and Cookies enabled to access this webcast.

Information you provide will be held in confidence and will be shared with the sponsoring vendor(s) of this webinar. We may use the information to contact you about your account and to let you know about related programs and products; you may opt-out at any time. This allows The Scientist to keep these webinars free of charge for our readers.

The Scientist c/o LabX Media Group
1000 N West Street, Suite 1200, Wilmington, Delaware, United States, 19801
Toll Free: 888.788.0328 | Phone: 705.528.6888
Email: privacy@the-scientist.com

Privacy Policy

© 1986-2022  The Scientist
 
The Scientist Logo_white

The Scientist needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.